Alkermes (ALKS) Capital Expenditures (2010 - 2026)
Alkermes' (ALKS) quarterly Capital Expenditures came in at $4.1 million in Q1 2026, down 59.55% year-on-year from $10.1 million in Q1 2025, and up 20550.0% on a QoQ basis from -$20000.0 in Q4 2025.
Alkermes (ALKS) Capital Expenditures (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Capital Expenditures data on file, last reported at $4.1 million in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 59.55% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $34.4 million, a 2.42% decrease from a year earlier, with the FY2025 full-year figure at $40.4 million, up 20.71% from the prior year.
- Capital Expenditures for Q1 2026 stood at $4.1 million, up from -$20000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for ALKS reached as high as $17.3 million in Q3 2025 and fell as low as -$20000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $9.7 million across 5 years, with a median of $9.8 million in 2024.
- Across the five-year window, Capital Expenditures soared 117.62% in 2022 and sank 100.2% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $10.0 million in 2022, then jumped by 69.82% to $17.0 million in 2023, then tumbled by 42.61% to $9.8 million in 2024, then plunged by 100.2% to -$20000.0 in 2025, then soared by 20550.0% to $4.1 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $4.1 million in Q1 2026, -$20000.0 in Q4 2025, and $17.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | 4.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.09 Mn |
| Mar 31, 2026 | 4.09 Mn |
| Dec 31, 2025 | -20,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Sep 30, 2025 | 17.31 Mn |
| Sep 30, 2025 | 17.31 Mn |
| Jun 30, 2025 | 13.02 Mn |
| Jun 30, 2025 | 13.02 Mn |
| Mar 31, 2025 | 10.11 Mn |
| Mar 31, 2025 | 10.11 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Sep 30, 2024 | 8.26 Mn |
| Sep 30, 2024 | 8.26 Mn |
| Jun 30, 2024 | 7.11 Mn |
| Jun 30, 2024 | 7.11 Mn |
| Mar 31, 2024 | 8.34 Mn |
| Mar 31, 2024 | 8.34 Mn |
| Dec 31, 2023 | 17.03 Mn |
| Dec 31, 2023 | 17.03 Mn |